News Breaks |
|
|
| September 5, 2012 |
| 09:04 EDT |  | BAX | Baxter begins Phase 1 clinical trial for anti-MIF antibody
Baxter has begun dosing patients with malignant solid tumors in a Phase I clinical trial of a monoclonal antibody. The candidate is a fully-human, recombinant anti-macrophage migration inhibitory factor monoclonal antibody with potential to be a new therapeutic agent in treatment of cancer. Monoclonal antibodies target a specific antigen in the body rather than traditional, systemic regimens. The Phase I, open label study is designed to assess the safety, tolerability and optimal dose of the antibody in up to 44 adult patients with malignant solid tumors. |
|
|
News For BAX From The Last 14 Days Check below for free stories on BAX the last two weeks. |
|
|
| May 21, 2013 |
| 09:09 EDT | | BAX | Baxter granted authorization by European Commission for use of HyQvia
Baxter International (BAX) and Halozyme Therapeutics (HALO) announced that the European Commission has granted Baxter marketing authorization in all European Union Member States for the use of HyQvia as replacement therapy for adult patients with primary and secondary immunodeficiencies. Baxter will introduce HyQvia in select countries during 2013 and plans to expand the launch to other EU countries in 2014. |
|
| May 13, 2013 |
| 09:44 EDT |  | BAX | Several companies reportedly interested in buying Adcock Ingram, Globes says
 Subscribe for More Information |
|
| May 10, 2013 |
| 11:59 EDT |  | BAX | Options with decreasing implied volatility: GRPN DGIT BMC BAX TRIP
Subscribe for More Information |
|
| May 9, 2013 |
| 05:54 EDT | | BAX | Stocks with implied volatility movement; DELL BAX
Subscribe for More Information |
|
|
|
|
|
